@momoonla @dbdugger I agree. It's been a huge and long battle w pharma to gain legal rights re manufacure & distribute inexpensive and/or generic HIV meds here's an informative article on this: https://t.co/frap69On3u
They were on the wrong side of history, as 2001-2011 saw an impressive rise in the use of ARTs in Africa. This was lauded by some as, “one of the most important programmes in global health.” ARTs > VMMC https://t.co/M2m2uLcFVt https://t.co/a1GTPsiC4v
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @zarinanteta: Great thread on the role of India in manufacturing generics. They’ll likely do same for Covid vaccine. Medication is so ch…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
Great thread on the role of India in manufacturing generics. They’ll likely do same for Covid vaccine. Medication is so cheap in India, I would buy my contraceptive pill OTC for 1/3 of the cost here in SA.
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
RT @paimadhu: After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufactu…
After a lot of global advocacy, widespread access to affordable ARVs became feasible after Cipla, a generics Indian manufacturer offered triple therapy for less than a dollar a day. Full story here: https://t.co/BTMKWljYlM
@JoiaMukherjee #peoplesvaccine We proved w HIV how to do it right. "High cost...reduced through...access to generic drugs; care...simplified through public health approach...; lack of human resources...through task-shifting to non-physicians." See here:
"HIV/AIDS was considered a humanitarian emergency, requiring a simple, rapid emergency response to reduce mortality as quickly as possible. To provide effective, affordable care to the millions adaptations to the Western model of care were required" https:
antiretroviral therapy in Africa ..... http://t.co/1TUKvgqh .... #globalhealth #publichealth #epidemiology #healthpolicy #healtheconomics
The first decade of antiretroviral therapy in Africa http://t.co/1TUP2Qrb
The first decade of antiretroviral therapy in Africa Nathan Ford et al.: Globalization and Health 2011, 7:33... http://t.co/gCaZJOk8
“Challenge for next decade is to increase access so ALL patients everywhere can benefit” from latest fruits of science. http://t.co/HdS2fXoG
"Those opposing ART scale up in Africa argued it was untested. Now clear treating HIV on large scale is entirely poss" http://t.co/HdS2fXoG
"1st Decade of ART in Africa" in @GHJournal by @MSF_access' Ford & adherence experts: lessons/roadmap for next 10 yrs. http://t.co/HdS2fXoG